ArticleJournal of obesity & metabolic syndrome2026
Comparative Clinical Analysis of DPP-4 inhibitors and SGLT2 Inhibitors: A Real-World Switch Study.
Article in Journal of obesity & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose co-transporter 2 (SGLT2) inhibitors are contemporary oral antidiabetic medications, each offering distinct advantages and challenges. Understanding their comparative effectiveness in real-world settings is crucial for optimizing treatment strategies. Methods: We retrospectively analyzed adults with type 2 diabetes mellitus who switched between DPP-4 inhibitors and SGLT2 inhibitors from December 1, 2014, to November 26, 2023, using a clinical data warehouse. All participants had baseline glycosylated hemoglobin (HbA1c) levels between 6.5% and 10.0% and were receiving metformin. To reduce baseline imbalance in HbA1c and fasting plasma glucose (FPG), we excluded patients with an estimated glomerular filtration rate <45 mL/min/1.73 m² and performed 1:1 propensity-score matching on baseline levels of HbA1c and FPG. The matched cohort included 168 patients (84 per group). The primary outcome was the between-group difference in change in HbA1c over 3 months. Secondary outcomes were changes in FPG, body mass index (BMI), liver enzymes, and renal function. Results: Switching to DPP-4 inhibitors was associated with a greater reduction in HbA1c (β, -0.26; 95% confidence interval [CI], -0.51 to -0.01; Conclusion: Transitioning to DPP-4 inhibitors reduced HbA1c levels significantly, whereas switching to SGLT2 inhibitors improved FPG and liver-related metabolic parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.